A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults
Frontiers in pharmacology（2022）
Key words
pharmacokinetics,pharmacodynamics,immunogenicity,denosumab,RANK,RANKL,osteoporosis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined